Inventiva (NASDAQ:IVA - Get Free Report)'s stock had its "buy" rating reissued by HC Wainwright in a research note issued to investors on Monday, Benzinga reports. They currently have a $22.00 price objective on the stock. HC Wainwright's price target points to a potential upside of 497.83% from the company's current price.
Other analysts also recently issued reports about the stock. Lifesci Capital reissued an "outperform" rating on shares of Inventiva in a report on Friday, January 5th. Stifel Nicolaus reduced their price target on shares of Inventiva from $27.00 to $25.00 and set a "buy" rating for the company in a report on Friday, February 16th. Eight research analysts have rated the stock with a buy rating, According to MarketBeat, Inventiva currently has an average rating of "Buy" and an average target price of $15.67.
Check Out Our Latest Research Report on IVA
Inventiva Stock Performance
NASDAQ:IVA traded up $0.06 during midday trading on Monday, reaching $3.68. The stock had a trading volume of 19,249 shares, compared to its average volume of 37,746. Inventiva has a 1-year low of $2.22 and a 1-year high of $5.05. The firm's fifty day simple moving average is $3.73 and its 200-day simple moving average is $3.98.
Institutional Investors Weigh In On Inventiva
Hedge funds have recently made changes to their positions in the company. Morgan Stanley increased its position in shares of Inventiva by 300.0% during the 4th quarter. Morgan Stanley now owns 6,000 shares of the company's stock worth $27,000 after purchasing an additional 4,500 shares in the last quarter. Commonwealth Equity Services LLC acquired a new stake in Inventiva in the 1st quarter valued at about $51,000. Finally, Citigroup Inc. increased its position in Inventiva by 91.7% in the 1st quarter. Citigroup Inc. now owns 23,000 shares of the company's stock valued at $84,000 after acquiring an additional 11,000 shares in the last quarter. Institutional investors and hedge funds own 19.06% of the company's stock.
About Inventiva
(
Get Free Report)
Inventiva SA, a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH) and other diseases. Its lead product candidate is Lanifibranor, which is in Phase III clinical trial to treat NASH. The company also develops Odiparcil, which has completed Phase IIa clinical trial for the treatment of mucopolysaccharidoses type VI disease.
Recommended Stories
Before you consider Inventiva, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Inventiva wasn't on the list.
While Inventiva currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.
Get This Free Report
